Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease

Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associat...

Full description

Saved in:
Bibliographic Details
Published inBrain (London, England : 1878) Vol. 131; no. 11; pp. 2851 - 2859
Main Authors Leoni, Valerio, Mariotti, Caterina, Tabrizi, Sarah J., Valenza, Marta, Wild, Edward J., Henley, Susie M. D., Hobbs, Nicola Z., Mandelli, Maria Luisa, Grisoli, Marina, Björkhem, Ingemar, Cattaneo, Elena, Di Donato, Stefano
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.11.2008
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients’ tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1–3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1–2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.
AbstractList Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.
Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.
Author Cattaneo, Elena
Henley, Susie M. D.
Hobbs, Nicola Z.
Leoni, Valerio
Wild, Edward J.
Mariotti, Caterina
Mandelli, Maria Luisa
Grisoli, Marina
Björkhem, Ingemar
Di Donato, Stefano
Tabrizi, Sarah J.
Valenza, Marta
Author_xml – sequence: 1
  givenname: Valerio
  surname: Leoni
  fullname: Leoni, Valerio
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 2
  givenname: Caterina
  surname: Mariotti
  fullname: Mariotti, Caterina
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 3
  givenname: Sarah J.
  surname: Tabrizi
  fullname: Tabrizi, Sarah J.
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 4
  givenname: Marta
  surname: Valenza
  fullname: Valenza, Marta
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 5
  givenname: Edward J.
  surname: Wild
  fullname: Wild, Edward J.
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 6
  givenname: Susie M. D.
  surname: Henley
  fullname: Henley, Susie M. D.
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 7
  givenname: Nicola Z.
  surname: Hobbs
  fullname: Hobbs, Nicola Z.
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 8
  givenname: Maria Luisa
  surname: Mandelli
  fullname: Mandelli, Maria Luisa
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 9
  givenname: Marina
  surname: Grisoli
  fullname: Grisoli, Marina
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 10
  givenname: Ingemar
  surname: Björkhem
  fullname: Björkhem, Ingemar
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 11
  givenname: Elena
  surname: Cattaneo
  fullname: Cattaneo, Elena
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
– sequence: 12
  givenname: Stefano
  surname: Di Donato
  fullname: Di Donato, Stefano
  organization: Unit Biochemistry and Genetics, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Neurodegenerative Disease and Dementia Research Centre, Institute of Neurology, University College London, UK, Department of Pharmacological Sciences and Centre for Stem Cell Research, University of Milan, Unit of Neuroradiology, Fondazione-IRCCS Istituto Neurologico Carlo Besta, Department of Bioengineering, Politecnico di Milano, Milan, Italy and Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20829215$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18772220$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:117814400$$DView record from Swedish Publication Index
BookMark eNqF0t1r1TAYB-AgE3c2vfNaiqC7sS5J89FejoPbGRxRNgUZQnhPmrpsbVKTlu3898a1nosh7CohefLxJr8DtOe8Mwi9JvgjwVVxvAlg3THcOUroM7QgTOCcEi720AJjLPKy4ngfHcR4gzFhBRUv0D4ppaSU4gX6-bWF2EFG2WV-va2Dv9_qa9-aOJjg2wxcnWkYaxhM9vniPLMu64PJO3C2SeZh3kBot9lqdIN1vwbvjmJW22ggmpfoeQNtNK_m9hB9P_30bbnK11_Ozpcn61xzWgy5MLxkpGwM8NKwRjJZ6brEmvMac1oLLAivK6EpCNOUG2xk2UAlNaVNQzmw4hDl077xzvTjRvXBdhC2yoNV89Bt6hnFBWWUJv9-8n3wv8dUh-ps1KZtwRk_RiUqyTEu2ZOQVKySglUJvn0Eb_wYXCo6Gc4KSaRM6M2Mxk1n6t01__1GAu9mAFFD2wRw2sado7ikVfra5OjkdPAxBtMobQcYrHdDCkOrCFZ_o6EeoqGmaKRFHx4t2p3_f340cT_2T8n59W0Kzf3OQrhVQhaSq9WPKyUvisvV1bJQ6-IPI2DYXg
CODEN BRAIAK
CitedBy_id crossref_primary_10_1007_s40618_014_0098_1
crossref_primary_10_1016_j_cca_2019_01_022
crossref_primary_10_1016_S1474_4422_11_70070_9
crossref_primary_10_1111_febs_15727
crossref_primary_10_3109_10715760903321804
crossref_primary_10_1016_j_bbalip_2014_12_018
crossref_primary_10_1007_s00018_012_1083_5
crossref_primary_10_1038_nm0309_253
crossref_primary_10_1111_j_1471_4159_2010_06912_x
crossref_primary_10_3390_antibiotics12010122
crossref_primary_10_1148_radiol_10091742
crossref_primary_10_1111_bph_16235
crossref_primary_10_3390_metabo14070394
crossref_primary_10_1016_j_tins_2017_05_002
crossref_primary_10_1038_nrdp_2015_5
crossref_primary_10_1111_j_1749_6632_2009_04943_x
crossref_primary_10_1002_jms_4827
crossref_primary_10_1038_s41537_020_00121_4
crossref_primary_10_15252_emmm_201505413
crossref_primary_10_1016_j_nbd_2021_105346
crossref_primary_10_1002_mds_28391
crossref_primary_10_1007_s11011_021_00844_y
crossref_primary_10_3233_JHD_170273
crossref_primary_10_3390_ijms25094696
crossref_primary_10_1111_epi_17232
crossref_primary_10_2478_jtim_2023_0142
crossref_primary_10_3390_ijms241311001
crossref_primary_10_1073_pnas_1002924107
crossref_primary_10_3390_biomedicines10061432
crossref_primary_10_1002_mds_25835
crossref_primary_10_1016_j_phrs_2023_106823
crossref_primary_10_3233_JHD_150170
crossref_primary_10_1016_j_expneurol_2014_04_021
crossref_primary_10_3389_fnagi_2022_797220
crossref_primary_10_15252_emmm_202012519
crossref_primary_10_1111_nan_12286
crossref_primary_10_3389_fnagi_2021_696778
crossref_primary_10_1016_j_bbalip_2016_09_011
crossref_primary_10_1016_j_neulet_2011_03_025
crossref_primary_10_1016_j_talo_2023_100278
crossref_primary_10_1111_nyas_14977
crossref_primary_10_1038_nrneurol_2014_24
crossref_primary_10_1177_0891988710383573
crossref_primary_10_3389_fneur_2022_940118
crossref_primary_10_1038_nrneurol_2011_132
crossref_primary_10_1016_j_parkreldis_2023_105488
crossref_primary_10_1042_BST20180135
crossref_primary_10_1517_17530059_2012_701205
crossref_primary_10_1016_j_chemphyslip_2011_04_002
crossref_primary_10_1038_cdd_2014_162
crossref_primary_10_1016_S1474_4422_09_70178_4
crossref_primary_10_1146_annurev_pharmtox_010715_103233
crossref_primary_10_1021_acs_biochem_5b00900
crossref_primary_10_1016_j_jchromb_2009_05_017
crossref_primary_10_3389_fneur_2021_657973
crossref_primary_10_3233_JHD_240030
crossref_primary_10_1051_medsci_2019253
crossref_primary_10_1093_brain_awz174
crossref_primary_10_1016_j_nbd_2013_03_013
crossref_primary_10_3390_biology14020129
crossref_primary_10_1016_j_nbd_2016_11_013
crossref_primary_10_1007_s13311_019_00731_6
crossref_primary_10_1016_j_neulet_2009_06_073
crossref_primary_10_14802_jmd_24232
crossref_primary_10_1523_JNEUROSCI_0917_10_2010
crossref_primary_10_1080_14789450_2020_1847086
crossref_primary_10_3390_cells13060469
crossref_primary_10_1016_j_bbi_2014_09_011
crossref_primary_10_1016_j_expneurol_2009_05_012
crossref_primary_10_3233_JHD_220552
crossref_primary_10_1016_j_bcp_2013_03_015
crossref_primary_10_1016_j_jns_2016_02_018
crossref_primary_10_1111_jnc_15228
crossref_primary_10_1194_jlr_R006338
crossref_primary_10_1007_s12035_024_04672_w
crossref_primary_10_1016_j_biochi_2012_09_025
crossref_primary_10_3390_ph16111513
crossref_primary_10_1002_lipd_12041
crossref_primary_10_1016_j_neurol_2012_07_003
crossref_primary_10_1016_j_fct_2018_05_059
crossref_primary_10_1152_physrev_00041_2009
crossref_primary_10_1186_s13578_023_01053_z
crossref_primary_10_1371_journal_pone_0070019
crossref_primary_10_1002_jcp_25488
crossref_primary_10_1016_j_bbrc_2014_01_188
crossref_primary_10_1186_s12868_014_0137_z
crossref_primary_10_1016_j_celrep_2022_111953
crossref_primary_10_3390_pharmaceutics13111897
crossref_primary_10_1016_j_jconrel_2020_12_051
crossref_primary_10_1371_journal_pone_0146480
crossref_primary_10_1007_s12010_021_03523_x
crossref_primary_10_1186_s13023_017_0742_x
crossref_primary_10_3389_fnsyn_2021_618391
crossref_primary_10_1038_s41598_020_76973_8
crossref_primary_10_1016_j_ymgme_2011_12_005
crossref_primary_10_1038_s41582_023_00864_5
crossref_primary_10_1016_j_tins_2011_06_005
crossref_primary_10_1093_brain_awv384
crossref_primary_10_1194_jlr_D058487
crossref_primary_10_1002_mds_28089
crossref_primary_10_1007_s00415_023_11572_x
crossref_primary_10_2217_fnl_11_38
Cites_doi 10.1016/S0140-6736(07)60111-1
10.1038/nrn1474
10.1212/WNL.54.2.452
10.1097/00005072-199805000-00001
10.1212/WNL.44.8.1533
10.1006/nimg.2001.0978
10.1016/0092-8674(93)90585-E
10.1161/01.ATV.0000120374.59826.1b
10.1021/pr0700753
10.1002/ana.20121
10.1006/abio.1995.1110
10.1074/jbc.M303415200
10.1073/pnas.96.13.7238
10.1007/s00018-003-3018-7
10.1212/01.WNL.0000065888.88988.6E
10.1073/pnas.93.18.9799
10.1523/JNEUROSCI.3355-05.2005
10.1194/jlr.R400004-JLR200
10.1111/j.1600-0404.2006.00684.x
10.1016/j.nbd.2007.07.004
10.1016/S0304-3940(02)00887-X
10.1212/01.WNL.0000132965.14653.D1
10.1016/j.brainresbull.2006.10.028
10.1016/S1474-4422(04)00964-0
10.1212/01.wnl.0000174432.87383.87
10.1093/hmg/ddm170
10.1111/j.1365-2796.2006.01725.x
10.1093/clinchem/34.12.2456
10.1002/mds.870110204
10.1038/nrn1806
10.1016/j.cell.2006.04.026
ContentType Journal Article
Copyright The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008
2008 INIST-CNRS
The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Copyright_xml – notice: The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2008
– notice: 2008 INIST-CNRS
– notice: The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
8FD
FR3
K9.
NAPCQ
P64
7X8
ADTPV
AOWAS
DOI 10.1093/brain/awn212
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
SwePub
SwePub Articles
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Neurosciences Abstracts

Nursing & Allied Health Premium
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2156
EndPage 2859
ExternalDocumentID oai_swepub_ki_se_562422
1590062631
18772220
20829215
10_1093_brain_awn212
10.1093/brain/awn212
ark_67375_HXZ_7R3SHZC3_L
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GrantInformation_xml – fundername: Telethon
  grantid: GGP06250
– fundername: Department of Health
– fundername: Medical Research Council
GroupedDBID ---
-E4
-~X
.2P
.55
.GJ
.I3
.XZ
.ZR
0R~
1CY
1TH
23N
2WC
354
3O-
4.4
41~
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6PF
70D
AABZA
AACZT
AAGKA
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
AAWDT
AAWTL
AAYJJ
ABDFA
ABDPE
ABEJV
ABEUO
ABGNP
ABIME
ABIVO
ABIXL
ABJNI
ABKDP
ABLJU
ABMNT
ABNGD
ABNHQ
ABNKS
ABPIB
ABPQP
ABPTD
ABQLI
ABQNK
ABSMQ
ABVGC
ABWST
ABXVV
ABXZS
ABZBJ
ABZEO
ACBNA
ACFRR
ACGFS
ACIWK
ACPQN
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEHUL
AEJOX
AEKPW
AEKSI
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFQV
AFFZL
AFGWE
AFIYH
AFOFC
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AI.
AIJHB
AJBYB
AJDVS
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
ANFBD
APIBT
APJGH
APWMN
AQDSO
AQKUS
ARIXL
ASAOO
ASPBG
ATDFG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AYOIW
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BR6
BSCLL
BSWAC
BTRTY
BVRKM
BZKNY
C1A
C45
CAG
CDBKE
COF
CS3
CXTWN
CZ4
DAKXR
DFGAJ
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EIHJH
EJD
ELUNK
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MBLQV
MBTAY
MHKGH
ML0
MVM
N4W
N9A
NGC
NLBLG
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OBOKY
OCZFY
ODMLO
OHH
OHT
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RIG
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCN
TCURE
TEORI
TJX
TLC
TMA
TR2
VH1
VVN
W8F
WH7
WOQ
X7H
X7M
XJT
XOL
YAYTL
YKOAZ
YQJ
YSK
YXANX
ZCG
ZGI
ZKB
ZKX
ZXP
~91
6.Y
AASNB
ABQTQ
ABSAR
ADJQC
ADRIX
AFXEN
F20
G8K
KC5
M49
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
8FD
FR3
K9.
NAPCQ
P64
7X8
ADTPV
AOWAS
ID FETCH-LOGICAL-c523t-6e58418fea58e4f7479cd80c55d052d60615d96c2a6ef8b0e78fa97c22ff25a43
ISSN 0006-8950
1460-2156
IngestDate Mon Sep 01 03:35:32 EDT 2025
Thu Jul 10 22:38:15 EDT 2025
Fri Jul 11 08:07:32 EDT 2025
Sun Jun 29 15:29:59 EDT 2025
Mon Jul 21 05:46:54 EDT 2025
Mon Jul 21 09:15:36 EDT 2025
Tue Jul 01 00:46:01 EDT 2025
Thu Apr 24 23:04:03 EDT 2025
Wed Aug 28 03:24:31 EDT 2024
Tue Aug 05 16:50:28 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords oxysterol
gas chromatography-mass spectrometry
24S-hydroxycholesterol
biomarker
caudate volume
MRI
Nervous system diseases
Huntington disease
Nuclear magnetic resonance imaging
Genetic disease
Cerebral disorder
Gas chromatography
Central nervous system disease
Degenerative disease
Mass spectrometry
Extrapyramidal syndrome
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c523t-6e58418fea58e4f7479cd80c55d052d60615d96c2a6ef8b0e78fa97c22ff25a43
Notes These authors contributed equally to this work.
ArticleID:awn212
istex:70A25D2A8E19E438C04F336B9AAF31AB06F8BB3B
ark:/67375/HXZ-7R3SHZC3-L
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://academic.oup.com/brain/article-pdf/131/11/2851/16694672/awn212.pdf
PMID 18772220
PQID 195437177
PQPubID 35133
PageCount 9
ParticipantIDs swepub_primary_oai_swepub_ki_se_562422
proquest_miscellaneous_69750084
proquest_miscellaneous_19497649
proquest_journals_195437177
pubmed_primary_18772220
pascalfrancis_primary_20829215
crossref_citationtrail_10_1093_brain_awn212
crossref_primary_10_1093_brain_awn212
oup_primary_10_1093_brain_awn212
istex_primary_ark_67375_HXZ_7R3SHZC3_L
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-11-01
PublicationDateYYYYMMDD 2008-11-01
PublicationDate_xml – month: 11
  year: 2008
  text: 2008-11-01
  day: 01
PublicationDecade 2000
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: England
PublicationTitle Brain (London, England : 1878)
PublicationTitleAlternate Brain
PublicationYear 2008
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References Aylward ( key 20170508031658_B2) 2004; 63
Björkhem ( key 20170508031658_B4) 2006; 185
Langbehn ( key 20170508031658_B16) 2004; 66
Lütjohann ( key 20170508031658_B20) 1996; 93
Whitwell ( key 20170508031658_B34) 2001; 22
Huntington Study ( key 20170508031658_B14) 1996; 11
Dalrymple ( key 20170508031658_B8) 2007; 6
Lund ( key 20170508031658_B18) 1999; 96
Lund ( key 20170508031658_B19) 2003; 278
Teunissen ( key 20170508031658_B27) 2005; 4
Valenza ( key 20170508031658_B30) 2007; 28
Leoni ( key 20170508031658_B17) 2002; 331
Gellera ( key 20170508031658_B11) 1996; 59
International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research group on Huntington's Chorea ( key 20170508031658_B15) 1994; 44
Huntington's Disease Collaborative Research Group ( key 20170508031658_B13) 1993; 72
Walker ( key 20170508031658_B33) 2007; 369
Cohn ( key 20170508031658_B7) 1988; 34
Valenza ( key 20170508031658_B29) 2007; 16
Aylward ( key 20170508031658_B1) 2007; 72
Valenza ( key 20170508031658_B31) 2005; 25
Cattaneo ( key 20170508031658_B6) 2005; 6
Dzeletovic ( key 20170508031658_B10) 1995; 225
Graham ( key 20170508031658_B12) 2006; 125
Taroni ( key 20170508031658_B26) 2004; 5
Reading ( key 20170508031658_B23) 2004; 55
Tzourio-Mazoyer ( key 20170508031658_B28) 2002; 15
Björkhem ( key 20170508031658_B3) 2006; 260
Vonsattel ( key 20170508031658_B32) 1998; 57
Björkhem ( key 20170508031658_B5) 2004; 24
Rosas ( key 20170508031658_B25) 2003; 60
Rosas ( key 20170508031658_B24) 2005; 65
Dietschy ( key 20170508031658_B9) 2004; 45
Marder ( key 20170508031658_B21) 2000; 54
Pfriger ( key 20170508031658_B22) 2003; 60
References_xml – volume: 369
  start-page: 218
  year: 2007
  ident: key 20170508031658_B33
  article-title: Huntington's disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60111-1
– volume: 5
  start-page: 641
  year: 2004
  ident: key 20170508031658_B26
  article-title: Pathways to motor incoordination: the inherited ataxias
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn1474
– volume: 54
  start-page: 452
  year: 2000
  ident: key 20170508031658_B21
  article-title: Rate of functional decline in Huntington's disease
  publication-title: Neurology
  doi: 10.1212/WNL.54.2.452
– volume: 57
  start-page: 369
  year: 1998
  ident: key 20170508031658_B32
  article-title: Huntington disease
  publication-title: J Neuropath Exp Neurol
  doi: 10.1097/00005072-199805000-00001
– volume: 44
  start-page: 1533
  year: 1994
  ident: key 20170508031658_B15
  article-title: Guidelines for the molecular genetics predictive test in Huntington's disease
  publication-title: Neurology
  doi: 10.1212/WNL.44.8.1533
– volume: 15
  start-page: 273
  year: 2002
  ident: key 20170508031658_B28
  article-title: Automated anatomical labelling of activations in spm using a macroscopic anatomical parcellation of the MNI MRI single subject brain
  publication-title: NeuroImage
  doi: 10.1006/nimg.2001.0978
– volume: 72
  start-page: 971
  year: 1993
  ident: key 20170508031658_B13
  article-title: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90585-E
– volume: 24
  start-page: 806
  year: 2004
  ident: key 20170508031658_B5
  article-title: Brain cholesterol: long secret life behind a barrier
  publication-title: Arterioscl Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000120374.59826.1b
– volume: 6
  start-page: 2833
  year: 2007
  ident: key 20170508031658_B8
  article-title: Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates
  publication-title: J Proteom Res
  doi: 10.1021/pr0700753
– volume: 66
  start-page: 81
  year: 2004
  ident: key 20170508031658_B16
  article-title: International Huntington's disease collaborative group. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length
  publication-title: Clin Genet
– volume: 55
  start-page: 879
  year: 2004
  ident: key 20170508031658_B23
  article-title: Functional brain changes in presymptomatic Huntington's disease
  publication-title: Ann Neurol
  doi: 10.1002/ana.20121
– volume: 225
  start-page: 73
  year: 1995
  ident: key 20170508031658_B10
  article-title: Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry
  publication-title: Anal Biochem
  doi: 10.1006/abio.1995.1110
– volume: 278
  start-page: 22980
  year: 2003
  ident: key 20170508031658_B19
  article-title: Knockout of the cholesterol-24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M303415200
– volume: 96
  start-page: 7238
  year: 1999
  ident: key 20170508031658_B18
  article-title: cDNA cloning of cholesterol 24-hydroxylase, a mediator of the cholesterol homeostasis in the brain
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.96.13.7238
– volume: 60
  start-page: 1158
  year: 2003
  ident: key 20170508031658_B22
  article-title: Cholesterol homeostasis and function in neurons of the central nervous system
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-003-3018-7
– volume: 60
  start-page: 1615
  year: 2003
  ident: key 20170508031658_B25
  article-title: Evidence for a more widespread cerebral pathology in early HD
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000065888.88988.6E
– volume: 93
  start-page: 9799
  year: 1996
  ident: key 20170508031658_B20
  article-title: Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.93.18.9799
– volume: 25
  start-page: 9932
  year: 2005
  ident: key 20170508031658_B31
  article-title: Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.3355-05.2005
– volume: 45
  start-page: 1375
  year: 2004
  ident: key 20170508031658_B9
  article-title: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal
  publication-title: J Lipid Res
  doi: 10.1194/jlr.R400004-JLR200
– volume: 185
  start-page: 43
  year: 2006
  ident: key 20170508031658_B4
  article-title: Oxysterols and Alzheimer's disease
  publication-title: Acta Neurol Scand Suppl
  doi: 10.1111/j.1600-0404.2006.00684.x
– volume: 28
  start-page: 133
  year: 2007
  ident: key 20170508031658_B30
  article-title: Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2007.07.004
– volume: 331
  start-page: 163
  year: 2002
  ident: key 20170508031658_B17
  article-title: Changes in human plasma levels of 24S-hydroxycholesterol during progression of multiple sclerosis
  publication-title: Neurosci Lett
  doi: 10.1016/S0304-3940(02)00887-X
– volume: 63
  start-page: 66
  year: 2004
  ident: key 20170508031658_B2
  article-title: Onset and rate of striatal atrophy in preclinical Huntington's disease
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000132965.14653.D1
– volume: 72
  start-page: 152
  year: 2007
  ident: key 20170508031658_B1
  article-title: Change in MRI striatal volumes as a biomarker in preclinical Huntington disease
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2006.10.028
– volume: 4
  start-page: 32
  year: 2005
  ident: key 20170508031658_B27
  article-title: Biological markers in CSF and blood for axonal degeneration in multiple sclerosis
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(04)00964-0
– volume: 65
  start-page: 745
  year: 2005
  ident: key 20170508031658_B24
  article-title: Regional cortical thinning in preclinical Huntington disease and its relationships to cognition
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000174432.87383.87
– volume: 59
  start-page: 475
  year: 1996
  ident: key 20170508031658_B11
  article-title: Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene
  publication-title: Am J Hum Genet
– volume: 16
  start-page: 2187
  year: 2007
  ident: key 20170508031658_B29
  article-title: Cholesterol biosynthetic pathway is impaired in YAC128 mice and is related to huntingtin expression
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddm170
– volume: 260
  start-page: 493
  year: 2006
  ident: key 20170508031658_B3
  article-title: Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2006.01725.x
– volume: 34
  start-page: 2456
  year: 1988
  ident: key 20170508031658_B7
  article-title: Lipoprotein cholesterol concentrations in the plasma of human subjects measured in the fed and fasted states
  publication-title: Clin Chem
  doi: 10.1093/clinchem/34.12.2456
– volume: 11
  start-page: 136
  year: 1996
  ident: key 20170508031658_B14
  article-title: The unified Huntington's disease rating scale: reliability and consistency
  publication-title: Mov Dis
  doi: 10.1002/mds.870110204
– volume: 6
  start-page: 919
  year: 2005
  ident: key 20170508031658_B6
  article-title: Normal huntingtin function: an alternative approach to Huntington's disease
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn1806
– volume: 125
  start-page: 1179
  year: 2006
  ident: key 20170508031658_B12
  article-title: Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin
  publication-title: Cell
  doi: 10.1016/j.cell.2006.04.026
– volume: 22
  start-page: 1483
  year: 2001
  ident: key 20170508031658_B34
  article-title: Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging
  publication-title: Am J Neuroradiol
SSID ssj0014326
Score 2.315527
Snippet Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be...
SourceID swepub
proquest
pubmed
pascalfrancis
crossref
oup
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2851
SubjectTerms 24S-hydroxycholesterol
Adult
Biological and medical sciences
biomarker
Biomarkers - blood
Brain Mapping - methods
Caudate Nucleus - pathology
caudate volume
Cholesterol - blood
Cohort Studies
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Disease Progression
Female
gas chromatography-mass spectrometry
Gas Chromatography-Mass Spectrometry - methods
Humans
Huntington Disease - blood
Huntington Disease - pathology
Hydroxycholesterols - blood
Magnetic Resonance Imaging - methods
Male
Medical sciences
Middle Aged
MRI
Neurology
oxysterol
Prognosis
Young Adult
Title Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease
URI https://api.istex.fr/ark:/67375/HXZ-7R3SHZC3-L/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/18772220
https://www.proquest.com/docview/195437177
https://www.proquest.com/docview/19497649
https://www.proquest.com/docview/69750084
http://kipublications.ki.se/Default.aspx?queryparsed=id:117814400
Volume 131
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELbKJiEkhHinDEY-8PKhSpc6duJ8RIOpGxtCW4emaVLkOI6oBumUtgL6p_iL3Nlu2qBWA75EqX2x6txj--zcPUfIS1WwJNe58GF1wZAczvyM8sJHbjFAiO4pZRxkP0b9U3Zwxs9arV9LXkvTSdZVs5VxJf-jVSgDvWKU7D9otm4UCuAe9AtX0DBc_0rHn8D0_SY7lJ34X37m6JCCk5nhPhhZCgAlp7il7xwd7xt_8Ur7SHhRgIyp14bfuG_zRRgzMB43PtrU3EdyWK5M_2HPFEQsls4UDvXIZIrqfIblp7KeXo6zAB1Ehi70ECMP61VhILNqOBvWp9Sdg-68ClspZ9KFFk1k46RCuJC9el-7OgKyMTtHvkgsEW1X2wmZRYEPZknUmLHdwuGg2VuegIXjr9Xzn8nKhcKSaGWVOX7Zk99L6ry5m-Tb60RvkE0K-xJMmfFu_0P92YqFJr9f3REXaQEt7Jjnd-zTDRtoE4fzj3l85e0rOYbBWdisKqu2PX9w2ho7aHCX3HEbGO-tReM90tLlfXLzyLloPCAXFpTealB6gBjPgdIDUHrD0lsGpak3oPQWoHwz9hwkH5LTvfeD3b7vUnj4itNw4kcaDNyeKLTkQrMC9q6JykWgOM8DTvMIDeo8iRSVkS5EFuhYFDKJFaVFQblk4SOyUY5K_YR4mK-Yq1gFQnKW53nGkoxrnqgI5KGiTTrzl5oqx2-PaVa-ptbPIkyNClKrgjZ5VUtfWV6XNXKvjX5qIVldoi9kzNP-2XkaH4cn_fPdMD1sEw8UeE1b2w3t1sIUA9wB5G2yNVd36qaZcYqUjGHci6GDL-paWAPww54s9WiKIgx2FSxZLwHviGPqjDZ5bFG0-KMCcUwD6KiFVV2DxPOu6BLudMoxlow-vb6jW-TWYvw_IxuTaqqfg-0-ybbNePkNJdjwfw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+24S-hydroxycholesterol+and+caudate+MRI+in+pre-manifest+and+early+Huntington%27s+disease&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Leoni%2C+Valerio&rft.au=Mariotti%2C+Caterina&rft.au=Tabrizi%2C+Sarah+J.&rft.au=Valenza%2C+Marta&rft.date=2008-11-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=131&rft.issue=11&rft.spage=2851&rft.epage=2859&rft_id=info:doi/10.1093%2Fbrain%2Fawn212&rft.externalDocID=10.1093%2Fbrain%2Fawn212
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon